iShares Biotechnology ETF
871 hedge funds and large institutions have $4.59B invested in iShares Biotechnology ETF in 2024 Q4 according to their latest regulatory filings, with 117 funds opening new positions, 208 increasing their positions, 322 reducing their positions, and 114 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more ownership
Funds ownership: →
more first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
11% less capital invested
Capital invested by funds: $5.16B → $4.59B (-$565M)
35% less repeat investments, than reductions
Existing positions increased: 208 | Existing positions reduced: 322
49% less call options, than puts
Call options by funds: $424M | Put options by funds: $829M
Holders
871
Holding in Top 10
11
Calls
$424M
Puts
$829M
Top Buyers
| 1 | +$73M | |
| 2 | +$47.4M | |
| 3 | +$45.2M | |
| 4 |
Morgan Stanley
New York
|
+$44.4M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$31.4M |
Top Sellers
| 1 | -$143M | |
| 2 | -$71.8M | |
| 3 | -$37.4M | |
| 4 |
JP Morgan Chase
New York
|
-$36.1M |
| 5 |
LPL Financial
San Diego,
California
|
-$27.1M |